Article

Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms Reply

Department of Urology, University of Michigan, Ann Arbor, MI 48109-2800, USA.
New England Journal of Medicine (Impact Factor: 54.42). 07/2012; 367(3):248-57. DOI: 10.1056/NEJMcp1106637
Source: PubMed

ABSTRACT A 59-year-old man with a history of benign prostatic hyperplasia and lower urinary tract symptoms comes for care. He has been receiving doxazosin at a dose of 4 mg daily (his only medication) for the past 2 years, with minimal improvement. He continues to have nocturia, a weak urinary stream, and urinary frequency (voiding eight times per day). How would you manage this case?

0 Followers
 · 
145 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Self-report assessment of lower urinary tract symptoms (LUTS) is complicated by the many tools that are available. The International Prostate Symptom Score (IPSS) is widely used and highly recommended in review articles and practice guidelines. This review focuses on work completed since 2011 using the IPSS and other tools. The focus of the review is on the merits and weakness of existing tools, as well as a discussion of how to move the field forward, given that there is already a strong base of questionnaires. Some specific trends in health measurement include the use of item response theory and computer adaptive testing, but it is unclear to what extent they will be adopted within urology. Many current studies in urology are making use of single items to assess important symptoms of interest, such as nocturia and incontinence, so future work might seek to catalogue best-in-class, single-question items.
    Current Urology Reports 10/2012; 13(6). DOI:10.1007/s11934-012-0286-5 · 1.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many clinically localized prostate cancers that are diagnosed today are low risk, and prevention of disease-specific mortality may only be realized decades after treatment. Radical prostatectomy (RP) may adversely impact health-related quality of life (HRQOL) by causing both transient or permanent urinary incontinence and erectile dysfunction. In contrast, RP may also improve HRQOL via relief of lower urinary tract symptoms in men suffering from these symptoms prior to surgery. Because the average man treated for prostate cancer has a life expectancy of approximately 14 years, it is imperative to consider the long-term impact of RP on both survival and HRQOL in treatment decision making. This comprehensive literature review examines short-, intermediate-, and long-term HRQOL following RP. In addition, the long-term results of RP are compared with other treatment modalities for treating clinically localized prostate cancer.
    Reviews in urology 01/2013; 15(4):161-177.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives. Dutasteride, a dual 5α-reductase inhibitor, is used to treat benign prostatic hyperplasia. Nevertheless, its histopathological effects on the morphometrics of blood vessels and glands are still controversial. The aim here was to assess the histopathological effects of dutasteride in cases of benign prostatic hyperplasia in a retrospective study. Methods. Patients with benign prostatic hyperplasia more than 40 cm3 in prostatic volume were administered 0.5 mg of dutasteride daily or left untreated prior to receiving a transurethral resection of the prostate. Images of sections stained with hematoxylin/eosin and with anti-CD31 antibody were analyzed. Results. In the dutasteride-treated group, the duration of administration was 16.3 ± 8.1 weeks. Artery/arteriole density and vein/venule density in benign prostatic tissue were both lower in the dutasteride-treated group than in the control group. The vein/venule area as a percentage of the whole area was also lower in the dutasteride-treated group, while the artery/arteriole area did not show a significant difference. Glandular/CD31-expressing vessel densities as well as glandular/CD31-expressing vessel areas were comparable between the two groups. Conclusions. Dutasteride reduced the artery/arteriole and vein/venule densities and the proportion of vein/venule area in the tissue of patients with benign prostatic hyperplasia.
    01/2013; 2013(1):863489. DOI:10.1155/2013/863489
Show more